← Back to Search

Monoclonal Antibodies

Nivolumab for Liver Cancer

Phase < 1
Waitlist Available
Led By Laura Kulik, MD
Research Sponsored by Northwestern University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years post-treatment
Awards & highlights

Study Summary

This trial is testing nivolumab + yttrium-90 to see if it can better treat patients with liver cancer compared to other treatments.

Eligible Conditions
  • Liver Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years post-treatment
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years post-treatment for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Recurrence rate
Secondary outcome measures
Incidence of adverse events
Overall increase in future liver remnant (FLR)
Overall survival (OS)

Trial Design

1Treatment groups
Experimental Treatment
Group I: Treatment (yttrium Y 90 glass microspheres, nivolumab)Experimental Treatment2 Interventions
Patients receive standard of care yttrium Y 90 glass microspheres IV. Within 1-2 weeks of completing of yttrium-90 treatment, patients receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 2 weeks for up to 4 doses in the absence of disease progression or unacceptable toxicity. If imaging shows adequate FLR and at least stable disease, patients will undergo resection within 2 weeks after the last dose of nivolumab. Patients who do not complete resection due to feasibility and have progressed or have evidence of high-risk explant may continue to receive nivolumab IV every 2 weeks for up to 1 year.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Nivolumab
FDA approved
Yttrium Y 90 Glass Microspheres
2016
Completed Phase 2
~370

Find a Location

Who is running the clinical trial?

Northwestern UniversityLead Sponsor
1,589 Previous Clinical Trials
917,124 Total Patients Enrolled
8 Trials studying Liver Cancer
2,851 Patients Enrolled for Liver Cancer
Bristol-Myers SquibbIndustry Sponsor
2,641 Previous Clinical Trials
4,130,062 Total Patients Enrolled
6 Trials studying Liver Cancer
1,438 Patients Enrolled for Liver Cancer
National Cancer Institute (NCI)NIH
13,667 Previous Clinical Trials
40,926,164 Total Patients Enrolled
104 Trials studying Liver Cancer
26,668 Patients Enrolled for Liver Cancer

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Nivolumab and Yttrium-90 in Treating Patients With Liver Cancer Undergoing Surgical Resection
2019. "Nivolumab and Yttrium-90 in Treating Patients With Liver Cancer Undergoing Surgical Resection". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03812562.
~0 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top